DUBLIN--(BUSINESS WIRE)--The "Gallbladder Cancer - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Gallbladder Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 17, 5 and 2 respectively.
Companies Mentioned
- 4SC AG
- Advenchen Laboratories LLC
- Array BioPharma Inc
- Aslan Pharmaceuticals Pte Ltd
- Bayer AG
- BeiGene Ltd
- Eli Lilly and Co
- Halozyme Therapeutics Inc
- Hutchison MediPharma Ltd
- Ipsen SA
- Jiangsu Hengrui Medicine Co Ltd
- Kringl
Key Topics Covered
- Introduction
- Gallbladder Cancer - Overview
- Gallbladder Cancer - Therapeutics Development
- Gallbladder Cancer - Therapeutics Assessment
- Gallbladder Cancer - Companies Involved in Therapeutics Development
- Gallbladder Cancer - Drug Profiles
- Gallbladder Cancer - Dormant Projects
- Gallbladder Cancer - Discontinued Products
- Appendix
For more information about this report visit https://www.researchandmarkets.com/research/qm5wql/h1_2018_pipeline?w=4
